Arantza Onaindia

Dr. Arantza Onaindia

Surgical Pathology Department (Hematopathology, Dermatopathology), Hospital Universitario de Araba. 01009 Gasteiz, Araba, Spain
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Arantza OnaindiaArantza Onaindia
Arantza Onaindia
NSNancy Santiago-Quispe
Nancy Santiago-Quispe
EIErika Iglesias-Martinez
Erika Iglesias-Martinez
CRCristina Romero-Abrio
Cristina Romero-Abrio
Diffuse large B-cell lymphomas (DLBCLs) are aggressive B-cell neoplasms with considerable clinical, biologic, and pathologic diversity. The application of high throughput technologies to the study of lymphomas has yielded abundant molecular data leading to the identification of distinct molecular identities and novel pathogenetic pathways. In light of this new information, newly refined diagnostic criteria have been established in the fourth edition of the World Health Organization (WHO) consensus classification of lymphomas, which was revised in 2016. This article reviews the histopathological and molecular features of the various aggressive B-cell lymphoma subtypes included in the updated classification.

Verified
Journal Article
Open access
PDF file
JDJesús Frutos Díaz-Alejo
Jesús Frutos Díaz-Alejo
IPIvan Prieto-Potin
Ivan Prieto-Potin
RMRebeca Manso
Rebeca Manso
SRSocorro María Rodríguez-Pinilla
Socorro María Rodríguez-Pinilla
MRMarcos Rebollo-González
Marcos Rebollo-González
Arantza OnaindiaArantza Onaindia
Arantza Onaindia
Anaplastic Large Cell Lymphoma (ALCL) represents a diverse group of mature T-Cell Lymphomas unified by strong CD30 expression but with different molecular and clinical subtypes. This review summarizes recent molecular advances in ALCL, highlighting key discoveries that have refined its classification, diagnosis, and therapeutic strategies. ALCL comprises four major entities: systemic ALK-positive ALCL, systemic ALK-negative ALCL, Breast Implant-Associated ALCL (BIA-ALCL), and primary cutaneous ALCL. Each subtype exhibits unique phenotypes, along with cytogenetic and molecular alterations that affect clinical outcomes. Nevertheless, different oncogenic mechanisms mediate STAT3 activation. In ALK-positive ALCL, ALK fusion proteins drive oncogenesis via constitutive activation of STAT3 and other signaling pathways. ALK-negative ALCL comprises heterogeneous genetic subtypes, in which JAK/STAT3 pathway alterations and novel gene fusions are gaining recognition as potential therapeutic targets. This review emphasizes the need for integrative molecular diagnostics to improve stratification of ALCL subtypes and targeted treatment approaches. Future research should focus on elucidating the biological mechanisms underlying these alterations and on translating molecular insights into clinical practice.